In line with this view, xCT has been found overexpressed in several cancer types, including non-small cell lung cancer (NSLCL), triple-negative breast cancer (TNBC), liver carcinoma, glioma, and renal cell carcinoma, and its elevated expression often correlates with poor prognosis and drug resistance [30–34]. This evidence concerns the gene SLC7A11 and cancer.